U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. Drugs (Pharmaceuticals), Shortages, Weight, GLP-1 RAs (Drug), Prices (Fares, Fees and Rates), Telemedicine, Obesity, Eli Lilly and Company, Food and Drug Administration, Hims & Hers Health Inc, Novo Nordisk A/S, Jorgensen, Lars Fruergaard, Makary, Marty Read More
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
